| Over a month ago | ||||
Panmure Gordon analyst… Panmure Gordon analyst Mike Mitchell downgraded Dechra Pharmaceuticals to Hold from Buy with a price target of 3,750 GBp, down from 4,357 GBp. The analyst sees "limited further headroom" on the stock's valuation given increasing cost pressures. | ||||
RBC Capital analyst Zoe… RBC Capital analyst Zoe Karamanoli upgraded Dechra Pharmaceuticals to Outperform from Sector Perform with a price target of 4,200 GBp, down from 5,300 GBp. The analyst says Dechra is a "well-run compound growth story" with an attractive valuation at current share levels. The company has strong market trends with revenue that should be defensive in periods of consumer downturn, Karamanoli tells investors in a research note. | ||||
| Over a quarter ago | ||||
Liberum analyst Alistair… Liberum analyst Alistair Campbell upgraded Dechra Pharmaceuticals to Hold from Sell with a 4,020 GBp price target. The analyst believes the company's first half results on Monday should offer support for the shares. He upgrades Dechra to Hold with the stock down 28% year-to-date. | ||||
Panmure Gordon analyst… Panmure Gordon analyst Mike Mitchell upgraded Dechra Pharmaceuticals to Buy from Hold with a 4,357 GBp price target. | ||||
JPMorgan analyst James… JPMorgan analyst James Gordon raised the firm's price target on Dechra Pharmaceuticals to 5,700 GBp from 5,400 GBp and keeps an Overweight rating on the shares. | ||||
RBC Capital analyst… RBC Capital analyst Charles Weston raised the firm's price target on Dechra Pharmaceuticals to 5,300 GBp from 4,400 GBp and keeps a Sector Perform rating on the shares. | ||||
JPMorgan analyst James… JPMorgan analyst James Gordon raised the firm's price target on Dechra Pharmaceuticals to 5,400 GBp from 5,200 GBp and keeps an Overweight rating on the shares. | ||||
Stifel analyst Max… Stifel analyst Max Herrmann downgraded Dechra Pharmaceuticals to Hold from Buy with a price target of 5,185 GBp, up from 4,900 GBp. The analyst cites valuation for the downgrade, seeing little upside from current share levels. | ||||
